ANVS
Annovis Bio, Inc.
$1.93
+0.01 (+0.52%)
At close · Jul 2
Market Cap
$66.87M
Shares
34,646,868
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.93
Open$1.93
Day$1.89–2.02
52W$1.55–5.50
Avg vol 30d1.2M
Short int4.8M · 13.9% float · 4.0d
Short vol64%
Last earningsMay 15, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−24% below
◦
Price vs 50-day avg
−1% below
◦
RSI (14)
55 · neutral
+
MACD trend
positive
−
52-week position
10% · near low
Sentiment · smart money
Very Bullish
◦
Trend (MA cross)
50d $2 › 200d $3 — 200d above 50d
+
Institutional flow
+5% holders QoQ · +13 funds added
+
Insider flow
Net +$142.8K over 90 days · 0% sells
+
Short interest
13.87% of float · ▼ -4.3% MoM · 4.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
58 holders — near 3-yr high, broad support
Fundamentals
Excellent
+
EPS growth
+39% Y/Y
+
Balance sheet
net cash $19.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 15, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−24% below
Bearish
Price vs 50-day avg
−1% below
Neutral
RSI (14)
55 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
10% · near low
Bearish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +13 funds added
Insider flow
Accumulating
Net +$142.8K over 90 days · 0% sells
Short interest
Falling
13.87% of float · ▼ -4.3% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
58 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 10%
52-wk high $6
vs 200-day avg -24%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| PD open-label extension (OLE) study enrollment | 40% | Q1 2026 | — |
| Phase 3 AD trial enrollment | 85% | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANVS
this stock
Annovis Bio, Inc.
|
$66.87M | -44.2% | — | — | 13.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANVS | +17.0% | +4.3% | -50.8% | +3.8% | -44.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +15.5% | +5.6% | -58.8% | +4.0% | -53.4% |